Literature DB >> 33125799

Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington's Disease.

Thomas B Stoker1, Katie E R Andresen1, Roger A Barker1,2.   

Abstract

Entities:  

Year:  2020        PMID： 33125799      PMCID： PMC7894279          DOI： 10.1002/mds.28359

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  4 in total

1.  Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.

Authors:  Eugenio Mercuri; Basil T Darras; Claudia A Chiriboga; John W Day; Craig Campbell; Anne M Connolly; Susan T Iannaccone; Janbernd Kirschner; Nancy L Kuntz; Kayoko Saito; Perry B Shieh; Már Tulinius; Elena S Mazzone; Jacqueline Montes; Kathie M Bishop; Qingqing Yang; Richard Foster; Sarah Gheuens; C Frank Bennett; Wildon Farwell; Eugene Schneider; Darryl C De Vivo; Richard S Finkel
Journal:  N Engl J Med       Date:  2018-02-15       Impact factor: 91.245

2.  Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.

Authors:  Richard S Finkel; Eugenio Mercuri; Basil T Darras; Anne M Connolly; Nancy L Kuntz; Janbernd Kirschner; Claudia A Chiriboga; Kayoko Saito; Laurent Servais; Eduardo Tizzano; Haluk Topaloglu; Már Tulinius; Jacqueline Montes; Allan M Glanzman; Kathie Bishop; Z John Zhong; Sarah Gheuens; C Frank Bennett; Eugene Schneider; Wildon Farwell; Darryl C De Vivo
Journal:  N Engl J Med       Date:  2017-11-02       Impact factor: 91.245

3.  Targeting Huntingtin Expression in Patients with Huntington's Disease.

Authors:  Sarah J Tabrizi; Blair R Leavitt; G Bernhard Landwehrmeyer; Edward J Wild; Carsten Saft; Roger A Barker; Nick F Blair; David Craufurd; Josef Priller; Hugh Rickards; Anne Rosser; Holly B Kordasiewicz; Christian Czech; Eric E Swayze; Daniel A Norris; Tiffany Baumann; Irene Gerlach; Scott A Schobel; Erika Paz; Anne V Smith; C Frank Bennett; Roger M Lane
Journal:  N Engl J Med       Date:  2019-05-06       Impact factor: 91.245

Review 4.  Huntingtin-lowering strategies for Huntington's disease.

Authors:  Roger A Barker; Motoki Fujimaki; Priya Rogers; David C Rubinsztein
Journal:  Expert Opin Investig Drugs       Date:  2020-08-14       Impact factor: 6.206
  4 in total
  3 in total

Review 1.  [Disease-modifying treatment approaches in Huntington disease : Past and future].

Authors:  Wiebke Frank; Katrin S Lindenberg; Alzbeta Mühlbäck; Jan Lewerenz; G Bernhard Landwehrmeyer
Journal:  Nervenarzt       Date:  2021-11-11       Impact factor: 1.297

Review 2.  Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases.

Authors:  Jacob Helm; Ludger Schöls; Stefan Hauser
Journal:  Pharmaceutics       Date:  2022-08-16       Impact factor: 6.525

3.  Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy.

Authors:  Maren Freigang; Petra Steinacker; Andreas Hermann; René Günther; Claudia Diana Wurster; Olivia Schreiber-Katz; Alma Osmanovic; Susanne Petri; Jan Christoph Koch; Kevin Rostásy; Björn Falkenburger; Albert Christian Ludolph; Markus Otto
Journal:  Orphanet J Rare Dis       Date:  2021-07-28       Impact factor: 4.123
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.